Indication: Multiple Sclerosis (MS)

A 12-Month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS), to investigate changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720) [FLUENT]



Principal Investigator: Robert Tillett, M.D.
Norton Neuroscience Institute

Sponsor: Novartis Pharmaceuticals Corp

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.